Home›Trial›NCT07011706
🔬NCT07011706Phase 2ACTIVE NOT RECRUITING

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Study Summary

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Conditions
Atopic DermatitisAtopicDermatitisADEczema
Interventions / Drugs
ATI-045Placebo
View on ClinicalTrials.gov ↗
Sponsor
ACRS
Aclaris Therapeutics
Dermatology
D37/100
Study Details
Enrollment110 participants
Primary Completion—
Lead SponsorAclaris Therapeutics, Inc.
Data Retrieved2026-04-11 02:52:15.810997+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.